Need professional-grade analysis? Visit stockanalysis.com
$9.24M
N/A
N/A
N/A
Liminatus Pharma, Inc. Class A Common Stock (LIMN) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $0.20, down 8.65% from the previous close.
Over the past year, LIMN has traded between a low of $0.17 and a high of $26.67. The stock has lost 96.0% over this period. It is currently 99.3% below its 52-week high.
Liminatus Pharma, Inc. Class A Common Stock has a market capitalization of $9.24M.
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Side-by-side comparison against top Healthcare peers.